Icotinib is a potent, highly selective EGFR inhibitor.23 It is the first targeted small-molecule drug developed by scientists in China for use as a novel type of anticancer treatment.24 Icotinib is effective in the treatment of ESCC in patients with high EGFR expression. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.